Focus on methods for preventing graft-versus-host disease (GvHD) following allo-HSCT, such as pharmacologic immune suppression and stem cell graft manipulation techniques.
PRESS RELEASE – INSIDE INFORMATION Following a post-hoc analysis of a Phase 3 trial demonstrating pain relief in patients with severe knee osteoarthritis, Biosenic applied for an international.
PRESS RELEASE Dr Nicco's new Chief Operating Officer (COO) position will give her a broader mandate at BioSenic, where she is currently responsible for R&D programs. Mont-Saint-Guibert, Belgium, January 10, 2024, 7.00 am CEST – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, and its subsidiary Medsenic SAS, today announces the promotion of Dr Carole Nicco to Chief Operating Officer (COO) in ad
BioSenic signs a new subscription agreement for a maximum of EUR 1.2M in convertible bonds Mont-Saint-Guibert, Belgium, January 8, 2024, 6pm CEST – BIOSENIC , the company addressing unmet.